Literature DB >> 3279907

Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers.

M Boeckh1, H Lode, K Borner, G Höffken, J Wagner, P Koeppe.   

Abstract

The pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime were investigated in 10 healthy volunteers. The pharmacokinetic parameters showed no significant differences (P less than 0.05) between single and combined administration. No antagonistic effects were observed in serum bactericidal activity with the combination against 20 gram-positive and 20 gram-negative locally isolated bacteria. A titer of greater than or equal to 1:8 was generated by the combination against all test strains except enterococci. Seven of ten volunteers developed a typical "red man's syndrome" during the administration of 1.0 g of vancomycin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279907      PMCID: PMC172105          DOI: 10.1128/AAC.32.1.92

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections.

Authors:  J Klastersky; D Daneau; G Swings; D Weerts
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

2.  Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers.

Authors:  D P Healy; R E Polk; M L Garson; D T Rock; T J Comstock
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

3.  Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.

Authors:  L B Reller; C W Stratton
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

4.  Pharmacokinetics of vancomycin in anuria.

Authors:  B A Cunha; R Quintiliani; J M Deglin; M W Izard; C H Nightingale
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

5.  A program for non-linear regression analysis to be used on desk-top computers.

Authors:  P Koeppe; C Hamann
Journal:  Comput Programs Biomed       Date:  1980-12

6.  Vancomycin pharmacokinetics in normal and morbidly obese subjects.

Authors:  R A Blouin; L A Bauer; D D Miller; K E Record; W O Griffen
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

7.  Single-dose kinetics of intravenous vancomycin.

Authors:  D J Krogstad; R C Moellering; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  1980-04       Impact factor: 3.126

8.  Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia.

Authors:  J C Wade; S C Schimpff; K A Newman; P H Wiernik
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

9.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

10.  High performance liquid chromatographic assay of vancomycin in serum.

Authors:  J R Uhl; J P Anhalt
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

View more
  13 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

Review 3.  Antibiotic dosing in critically ill patients with acute kidney injury.

Authors:  Rachel F Eyler; Bruce A Mueller
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

4.  Application of a Bayesian method to monitor and adjust vancomycin dosage regimens.

Authors:  A K Hurst; M A Yoshinaga; G H Mitani; K A Foo; R W Jelliffe; E C Harrison
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Pharmacokinetics of vancomycin in adult cystic fibrosis patients.

Authors:  R A Pleasants; E L Michalets; D M Williams; W M Samuelson; J R Rehm; M R Knowles
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions.

Authors:  D P Healy; J V Sahai; S H Fuller; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

7.  Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".

Authors:  J Sahai; D P Healy; M J Shelton; J S Miller; S J Ruberg; R Polk
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

8.  Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.

Authors:  W Paulfeuerborn; H J Müller; K Borner; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 9.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

10.  Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations.

Authors:  Chie Emoto; Trevor N Johnson; Brooks T McPhail; Alexander A Vinks; Tsuyoshi Fukuda
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.